Garima Arora
Behavioral Neurology & Neuropsychiatry · Sugar Land, TXNPI 1497043137
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.1% of the total across 245 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 9.7% — the pattern of someone who eats at a lot of different presentations.
Across 245 payments — averaging $20.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$486
- Lundbeck LLC$480
- Sunovion Pharmaceuticals Inc.$478
- Takeda Pharmaceuticals U.S.A., Inc.$454
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$387
- UCB, Inc.$367
- plus $2K from 26 others
What the payments were for
- Food & beverage$4,90698%
- Education$962%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 22 | $486 |
| Lundbeck LLC | 33 | $480 |
| Sunovion Pharmaceuticals Inc. | 29 | $478 |
| Takeda Pharmaceuticals U.S.A., Inc. | 30 | $454 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 15 | $387 |
| UCB, Inc. | 15 | $367 |
| AbbVie(2 entities) | 13 | $251 |
| Acadia Pharmaceuticals Inc | 9 | $233 |
| Otsuka America Pharmaceutical, Inc. | 13 | $208 |
| Teva Pharmaceuticals USA, Inc. | 4 | $183 |
| SK Life Science, Inc. | 3 | $172 |
| Shire North American Group Inc | 10 | $145 |
| Neurocrine Biosciences, Inc. | 6 | $144 |
| Eisai Inc. | 6 | $133 |
| Biogen | 6 | $126 |
| Corium, LLC | 2 | $103 |
| Lilly USA, LLC | 4 | $86 |
| Abbott | 3 | $65 |
| Azurity Pharmaceuticals, Inc. | 3 | $55 |
| Boston Scientific | 1 | $55 |
| Merz Pharmaceuticals, LLC | 2 | $55 |
| Novartis | 3 | $52 |
| EMD Serono, Inc. | 2 | $50 |
| Genentech USA, Inc. | 2 | $40 |
| Livanova USA, Inc. | 2 | $39 |
| Averitas Pharma Inc. | 1 | $28 |
| TG Therapeutics, Inc. | 1 | $25 |
| Vanda Pharmaceuticals Inc. | 1 | $24 |
| Grifols USA, LLC | 1 | $23 |
| Jazz Pharmaceuticals Inc. | 1 | $23 |
| Supernus Pharmaceuticals, Inc. | 1 | $20 |
| OWP Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XCOPRI$125
- Austedo XR$122
- SPRAVATO$116
How this compares
Too few behavioral neurology & neuropsychiatry providers in Texasto place this figure against a meaningful peer group, so we don't.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 18 | $86,255 |
| RexultiBrexpiprazole | 26 | $55,169 |
| TrintellixVortioxetine Hydrobromide | 72 | $54,198 |
| Modafinil | 15 | $7,492 |
| Rivastigmine | 20 | $6,657 |
| Duloxetine Hcl | 282 | $6,355 |
| Mirtazapine | 266 | $5,451 |
| Memantine Hcl ErMemantine Hcl | 53 | $4,161 |
| Aripiprazole | 170 | $3,459 |
| Lamotrigine ErLamotrigine | 11 | $3,190 |
| Memantine Hcl | 95 | $3,084 |
| Lisdexamfetamine Dimesylate | 12 | $2,915 |
| Clonazepam | 133 | $2,850 |
| Risperidone | 34 | $2,825 |
| Fluvoxamine Maleate | 34 | $2,550 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $233 | $86,25518 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $208 | $55,16926 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $454 | $54,19872 claims |
| Lilly USA, LLCOlanzapine | $86 | $35018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few behavioral neurology & neuropsychiatry providers in Texason file to place this against a meaningful peer group, so we don't.
Other behavioral neurology & neuropsychiatry in Sugar Land
- Paul SchulzHouston$854K
- John BertelsonAustin$313K
- Hilary ButellaThe Woodlands$34K
- Gabriel de ErausquinSan Antonio$3K
- David HunterHouston$1K
- Ricardo JorgeHouston$1K
- Melissa JonesHouston$885
- Tanveer KhanConroe$278
- Alicia ParkerSan Antonio$147
- Matthew AyersConroe$121
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.